• Black Twitter Icon
  • Black LinkedIn Icon

FDA Approves Merck's Keytruda for First-Line Use in NSCLC

October 28, 2016


Just a few weeks after the European Society of Medical Oncology (ESMO) Conference wrapped up in Denmark, the U.S. FDA has approved Keytruda (pembrolizumab) for first-line use. KEYNOTE-024 was presented at ESMO.


The trial showed a significant improvement in progression-free survival (median 10.3 months vs. 6.0 months; hazard ratio 0.50) and overall survival (80% vs. 72% of patients were alive at 6 months; hazard ratio 0.60) in patients with untreated non-small cell lung cancer (NSCLC) whose tumours show at least 50% PD-L1 expression, compared to chemotherapy. PD-L1 is a biomarker which helps identify patients most likely to benefit from Keytruda. About 30% of all NSCLC have tumours with high PD-L1 expression and would be eligible for first-line Keytruda.


The FDA issued approval of Keytruda in the first line setting, in patients whose tumours have high PD-L1 expression, almost two full months ahead of its target decision date of December 24, 2016. Keytruda is the first immunotherapy approved for the first-line treatment of NSCLC.

Please reload

Featured Posts

Revolutionizing Healthcare with Blockchain Technology

June 6, 2018

Please reload

Recent Posts

February 7, 2020

February 4, 2020

Please reload

Search By Tags